Merck KGaA Guidance Upgrade Sparks Undervaluation Debate
Merck KGaA's (XTRA:MRK) recent upgrade of its 2026 guidance has investors reevaluating the company's valuation. The pharmaceutical giant now expects group net sales to range from €21 billion to €21.8 billion and earnings per share before interest and taxes (EPS pre) to be between €7.90 and €8.60.
The stock price has responded positively, with a 9.45% return over the past 90 days and a 14.06% year-to-date increase. However, the company's one-year total shareholder return of 26.40% is in stark contrast to its performance over three and five years.
According to Simply Wall St, Merck KGaA may be undervalued at its current price of €138.35, with a fair value estimate of around €146.29. This implies a modest upside based on the company's cash flow and earnings profile discounted at 5.26%.
The Life Science segment is driving growth, particularly Process Solutions, which has seen double-digit organic growth, strong order intake, and a sustained book-to-bill ratio above 1. This is fueled by increasing global investment in biotechnology and advanced biologics manufacturing.